Hims, Keeps and other companies advertise topical finasteride with limited disclosures of side effects.

According to the FDA, they have not received official approval, and no comprehensive safety data has been submitted for them.

FDA warning on topical finasteride: The FDA issued a warning about the topical form of finasteride (generic Propecia), often ...

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

A quick spray of medication might seem like an easy way to get thicker hair, but some people say one sold online has left ...

Commissioner Marty Makary said he has no plans to change current policy to restrict access to the abortion pill mifepristone, ...

This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

Hims & Hers Health (HIMS) stock declined about 2% yesterday. The fall came after the U.S. Food and Drug Administration (FDA) ...